Capricor Therapeutics (NASDAQ:CAPR) Stock Crosses Above 50-Day Moving Average - Here's What Happened

Key Points

• Capricor shares crossed above their 50-day moving average of $8.10, reaching $8.32 before last trading at $8.24 on volume of about 4.4 million shares.
• Analyst views are mixed: MarketBeat reports a consensus Hold rating and average price target of $30.25, while recent recommendations range from strong sell to buy.
• The biotech reported a quarterly loss of $0.70 per share, missing analyst expectations of a $0.59 loss; analysts forecast a full-year loss of $1.71 per share.

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report)'s share price crossed above its fifty day moving average during trading on Tuesday. The stock has a fifty day moving average of $8.10 and traded as high as $8.32. Capricor Therapeutics shares last traded at $8.24, with a volume of 4,395,381 shares changing hands.

Analyst Ratings Changes

CAPR has been the subject of several recent analyst reports. Weiss Ratings restated a "sell (d-)" rating on shares of Capricor Therapeutics in a research report on Friday, September 11th. Wall Street Zen cut Capricor Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday, August 1st. B. Riley Financial upgraded Capricor Therapeutics from a "neutral" rating to a "buy" rating and boosted their price objective for the stock from $5.00 to $21.00 in a research report on Monday, September 14th. JonesTrading downgraded Capricor Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, July 31st. Finally, Oppenheimer reissued an "outperform" rating on shares of Capricor Therapeutics in a report on Thursday, October 8th. Four research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $30.25.

Capricor Therapeutics Stock Performance

The stock has a market cap of $479.07 million, a price-to-earnings ratio of -3.36 and a beta of 0.80. The company's 50 day simple moving average is $8.10 and its 200 day simple moving average is $20.43.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing analysts' consensus estimates of ($0.59) by ($0.11). Sell-side analysts predict that Capricor Therapeutics, Inc. will post -1.71 EPS for the current year.

Institutional Investors Weigh In On Capricor Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. KBC Group NV bought a new position in Capricor Therapeutics during the 1st quarter valued at $44,000. Activest Wealth Management increased its position in shares of Capricor Therapeutics by 100.0% during the 3rd quarter. Activest Wealth Management now owns 4,000 shares of the biotechnology company's stock valued at $38,000 after purchasing an additional 2,000 shares during the period. Quantinno Capital Management LP increased its position in shares of Capricor Therapeutics by 16.8% during the 1st quarter. Quantinno Capital Management LP now owns 14,472 shares of the biotechnology company's stock valued at $440,000 after purchasing an additional 2,083 shares during the period. Glenmede Trust Co. NA raised its stake in shares of Capricor Therapeutics by 13.2% in the 1st quarter. Glenmede Trust Co. NA now owns 36,330 shares of the biotechnology company's stock worth $1,104,000 after buying an additional 4,240 shares in the last quarter. Finally, Sei Investments Co. raised its stake in shares of Capricor Therapeutics by 41.2% in the 1st quarter. Sei Investments Co. now owns 17,805 shares of the biotechnology company's stock worth $541,000 after buying an additional 5,195 shares in the last quarter. Institutional investors own 21.68% of the company's stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a biotechnology company focused on developing cell and exosome-based therapies for serious diseases. The company's research and development programs are designed to address conditions involving muscle degeneration, inflammation and tissue damage.

Capricor's lead investigational product is deramiocel, also known as CAP-1002, an allogeneic cardiac-derived cell therapy being developed for Duchenne muscular dystrophy. The company has also developed an exosome-based technology platform intended to support the delivery of therapeutic proteins, nucleic acids and other biological materials.

Founded in 2005, Capricor is headquartered in San Diego, California, and conducts its development activities primarily in the United States while working with research, clinical and commercial partners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.